Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Are Capecitabine and the Active Metabolite 5-FU CNS Penetrable to Treat Breast Cancer Brain Metastasis?

Jinqiang Zhang, Lingli Zhang, Yumei Yan, Shaorong Li, Liang Xie, Wei Zhong, Jing Lv, Xiuhua Zhang, Yu Bai and Ziqiang Cheng
Drug Metabolism and Disposition March 2015, 43 (3) 411-417; DOI: https://doi.org/10.1124/dmd.114.061820
Jinqiang Zhang
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lingli Zhang
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yumei Yan
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaorong Li
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liang Xie
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Zhong
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Lv
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiuhua Zhang
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Bai
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ziqiang Cheng
Drug Metabolism and Pharmacokinetics, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (J.Z., L.Z, Y.Y., S.L., Z.C.); Bioscience, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (L.X., J.L., X.Z., Y.B.); and Chemistry, Innovation Center China, Innovative Medicine and Early Development, AstraZeneca, Shanghai, China (W.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Brain metastasis (BM) is increasingly diagnosed in Her2 positive breast cancer (BC) patients. Lack of effective treatment to breast cancer brain metastases (BCBMs) is probably due to inability of the current therapeutic agents to cross the blood-brain barrier. The central nervous system (CNS) response rate in BCBM patients was reported to improve from 2.6%–6% (lapatinib) to 20%–65% (lapatinib in combination with capecitabine). Lapatinib is a poor brain penetrant. In this study, we evaluated the CNS penetration of capecitabine and hoped to interpret the mechanism of the improved CNS response from the pharmacokinetic (PK) perspective. Capecitabine does not have antiproliferative activity and 5-fluorouracil (5-FU) is the active metabolite. Capecitabine was orally administered to mouse returning an unbound brain-to-blood ratio (Kp,uu,brain) at 0.13 and cerebrospinal fluid (CSF)-to-unbound blood ratio (Kp,uu,CSF) at 0.29 for 5-FU. Neither free brain nor CSF concentration of 5-FU can achieve antiproliferative concentration for 50% of maximal inhibition of cell proliferation of 4.57 µM. BCBM mice were treated with capecitabine monotherapy or in combination with lapatinib. The Kp,uu,brain value of 5-FU increased to 0.17 in the brain tumor in the presence of lapatinib, which is still far below unity. The calculated free concentration of 5-FU and lapatinib in the brain tumor did not reach the antiproliferative potency and neither treatment showed antitumor activity in the BCBM mice. The CNS penetration of 5-FU in human was predicted based on the penetration in preclinical brain tumor, CSF, and human PK and the predicted free CNS concentration was below the antiproliferative potency. These results suggest that CNS penetration of 5-FU and lapatinib are not desirable and development of a true CNS penetrable therapeutic agent will further improve the response rate for BCBM.

Footnotes

    • Received October 29, 2014.
    • Accepted December 23, 2014.
  • dx.doi.org/10.1124/dmd.114.061820.

  • ↵Embedded ImageThis article has supplemental material available at dmd.aspetjournals.org.

  • Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 43 (3)
Drug Metabolism and Disposition
Vol. 43, Issue 3
1 Mar 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Are Capecitabine and the Active Metabolite 5-FU CNS Penetrable to Treat Breast Cancer Brain Metastasis?
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

CNS Penetration of 5-FU to Treat Breast Cancer Brain Metastasis

Jinqiang Zhang, Lingli Zhang, Yumei Yan, Shaorong Li, Liang Xie, Wei Zhong, Jing Lv, Xiuhua Zhang, Yu Bai and Ziqiang Cheng
Drug Metabolism and Disposition March 1, 2015, 43 (3) 411-417; DOI: https://doi.org/10.1124/dmd.114.061820

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

CNS Penetration of 5-FU to Treat Breast Cancer Brain Metastasis

Jinqiang Zhang, Lingli Zhang, Yumei Yan, Shaorong Li, Liang Xie, Wei Zhong, Jing Lv, Xiuhua Zhang, Yu Bai and Ziqiang Cheng
Drug Metabolism and Disposition March 1, 2015, 43 (3) 411-417; DOI: https://doi.org/10.1124/dmd.114.061820
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Functional Characterization of 29 CYP4F2 Variants
  • Exposure-toxicity relation of apatinib
  • ABC phenomenon potentiates anti-HCC efficacy
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics